These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 25614698)

  • 1. Comment on Retnakaran et al. Liraglutide and the preservation of pancreatic β-cell function in early type 2 diabetes: the LIBRA trial. Diabetes Care 2014;37:3270-3278.
    Arnolds S; Sawicki PT
    Diabetes Care; 2015 Feb; 38(2):e25. PubMed ID: 25614698
    [No Abstract]   [Full Text] [Related]  

  • 2. Response to Comment on Retnakaran et al. Liraglutide and the preservation of pancreatic β-cell function in early type 2 diabetes: the LIBRA trial. Diabetes Care 2014;37:3270-3278.
    Retnakaran R; Kramer CK; Zinman B
    Diabetes Care; 2015 Feb; 38(2):e26. PubMed ID: 25614699
    [No Abstract]   [Full Text] [Related]  

  • 3. Liraglutide and the preservation of pancreatic β-cell function in early type 2 diabetes: the LIBRA trial.
    Retnakaran R; Kramer CK; Choi H; Swaminathan B; Zinman B
    Diabetes Care; 2014 Dec; 37(12):3270-8. PubMed ID: 25249651
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical effects of liraglutide are possibly influenced by hypertriglyceridemia and remaining pancreatic β-cell function in subjects with type 2 diabetes mellitus.
    Tanabe A; Kaneto H; Kamei S; Hirukawa H; Shimoda M; Kimura T; Obata A; Okauchi S; Tatsumi F; Kohara K; Mune T; Kaku K
    J Diabetes Complications; 2016 Aug; 30(6):1201-3. PubMed ID: 27220544
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term liraglutide treatment is associated with increased insulin content and secretion in β-cells, and a loss of α-cells in ZDF rats.
    Schwasinger-Schmidt T; Robbins DC; Williams SJ; Novikova L; Stehno-Bittel L
    Pharmacol Res; 2013 Oct; 76():58-66. PubMed ID: 23891763
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Pharmacological and clinical profiles of a human GLP-1 analogue, liraglutide (Victoza(®))].
    Sugii H; Matsumura Y; Inoue A; Horigome H; Matsuzaki K; Shimizu A
    Nihon Yakurigaku Zasshi; 2010 Oct; 136(4):233-41. PubMed ID: 20948161
    [No Abstract]   [Full Text] [Related]  

  • 7. The development of non-peptide glucagon-like peptide-1 receptor agonist for the treatment of type 2 diabetes.
    Moon HS; Kim MK; Son MH
    Arch Pharm Res; 2011 Jul; 34(7):1041-3. PubMed ID: 21811909
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A review of efficacy and safety data regarding the use of liraglutide, a once-daily human glucagon-like peptide 1 analogue, in the treatment of type 2 diabetes mellitus.
    Montanya E; Sesti G
    Clin Ther; 2009 Nov; 31(11):2472-88. PubMed ID: 20109994
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Protective effects of glucagon-like peptide-1 on beta-cells: preclinical and clinical data].
    Consoli A; Di Biagio R
    G Ital Cardiol (Rome); 2011 Dec; 12(12 Suppl 2):5-9. PubMed ID: 22158421
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Letter to the Editor: Comment on "The Impact of Chronic Liraglutide Therapy on Glucagon Secretion in Type 2 Diabetes: Insight From the LIBRA Trial" by Kramer C.K., et al.
    Kalra S; Gupta Y
    J Clin Endocrinol Metab; 2015 Nov; 100(11):L116-7. PubMed ID: 26544663
    [No Abstract]   [Full Text] [Related]  

  • 11. Liraglutide: a once-daily human glucagon-like peptide-1 analogue.
    Aimaretti G
    J Endocrinol Invest; 2009 Sep; 32(8):701-3. PubMed ID: 19942822
    [No Abstract]   [Full Text] [Related]  

  • 12. Liraglutide protects pancreatic beta cells during an early intervention in Gato-Kakizaki rats.
    Luo X; Pan L; Nie A; Wang Q; Gu Y; Li F; Zhang H; Li W; Li X
    J Diabetes; 2013 Dec; 5(4):421-8. PubMed ID: 23590680
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The effects of glucagon-like peptide-1 on the beta cell.
    Vilsbøll T
    Diabetes Obes Metab; 2009 Dec; 11 Suppl 3():11-8. PubMed ID: 19878257
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of the long-acting human glucagon-like peptide-1 analog liraglutide on beta-cell function in normal living conditions.
    Mari A; Degn K; Brock B; Rungby J; Ferrannini E; Schmitz O
    Diabetes Care; 2007 Aug; 30(8):2032-3. PubMed ID: 17468345
    [No Abstract]   [Full Text] [Related]  

  • 15. Can early use of insulin, GLP-1 halt diabetes progression?
    Caffrey MK
    Am J Manag Care; 2014 Jul; 20(10 Spec No):E12. PubMed ID: 25830193
    [No Abstract]   [Full Text] [Related]  

  • 16. [Beta-cell function in the foreground. GLP-1 based therapy of type 2 diabetes].
    Kern W
    MMW Fortschr Med; 2010 Jan; 151 Suppl 4():173-8. PubMed ID: 21595145
    [No Abstract]   [Full Text] [Related]  

  • 17. Liraglutide: effects beyond glycaemic control in diabetes treatment.
    McGill JB
    Int J Clin Pract Suppl; 2010 Oct; (167):28-34. PubMed ID: 20887302
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Next-generation GLP-1 therapy: an introduction to liraglutide.
    Repas T
    Postgrad Med; 2011 Sep; 123(5):239-47. PubMed ID: 21904107
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Effects of glucagon-like peptide-1 on appetite and body weight: preclinical and clinical data].
    Sesti G
    G Ital Cardiol (Rome); 2011 Dec; 12(12 Suppl 2):10-6. PubMed ID: 22158422
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Therapies for the treatment of type 2 diabetes mellitus based on incretin action.
    Gallwitz B
    Minerva Endocrinol; 2006 Jun; 31(2):133-47. PubMed ID: 16682937
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.